Indeed, co-delivery of polyIC-R837@mPEG-PL-OA-IONPs (as TLR3-7 agonists) and OVA@mPEG-PL-OA-IONPs (as antigen) delayed tumor growth in OVA-expressing B16-bearing animals and led to tumor-free survival in some individuals, probably through an enhanced agonist effect on TLR signaling. This evidence concerns the gene TLR3 and neoplasm.